Folliculotropism in Actinic Keratoses in Patients not Responding to Treatments: A Pilot Study

Dear Editor,

Actinic keratoses (AK) have a high prevalence in the general population, with greater rates in Caucasian patients after the fourth and fifth decades of life (37.5-60.0%) (1,2). Standard histopathologic reporting of AKs does not provide information on the presence of atypical keratinocytes extending to the hair follicle, also defined as folliculotropism (FLC). Commonly, atypical cells in AKs do not present FLC, but this feature can be observed in bowenoid AKs with full-thickness epidermal atypia (3,4). FLC has been considered a possible element enhancing the chances of a progression toward invasive SCC (iSCC). Fernandez-Figueras et al. (3) reported that the depth of FLC in AKs was correlated with the invasiveness of associated iSCC. Pandey et al. (5) reported a positive association between AKs with FLC and history of invasive cutaneous cancer or melanoma, more often in men at an older age. The role of FLC in cutaneous melanoma is still debated, but it is considered a parameter that may correlate with treatment response in lentigo maligna and disease progression or recurrences in invasive tumors (6,7). These studies draw particular attention to the potential role of hair bulge compartment stem cells in favoring tumor progression through the expression of adhesion molecules, cytokines, and growth factor receptors (8).

Aks are known to have a high recurrence rate after topical treatment (1). The risk of evolution to an iSCC is not completely clear, but it has been estimated to be around 0.6% at 12 months and up to 2.5% at 48 months (1,3,7). Considering the possible progression and the heavy burden of AK treatments, including the economic burden, it is imperative to focus on histopathologic features associated with treatment failure. The aim of this preliminary study was to assess the histopathologic features, specifically FLC, of AK samples from patients considered "non-responders" to specific topical treatments. A secondary endpoint was to assess the clinical/dermoscopic features. Patients were considered "non-responders" if the lesions persisted after two alternated completed cycles of treatments with ingenol mebutate, imiguimod, diclofenac 3%, or 5-fluoruracil. Patients with a positive history of immunosuppression or genetic diseases were excluded. The study was approved by the local Ethics Committee.

Slides of AKs diagnosed at the Laboratory of Dermatopathology, University of Bologna, Italy from January 2016 to October 2018 were reviewed by two dermatopathologists (CM, PAF). 155 "non-responder" AKs of five main histopathologic subtypes were included, classified from grade I to III according to the




Figure 1. (a) Proliferative actinic keratoses showing periadnexal involvement of atypical keratinocytes (hematoxylin and eosin, ×20); (b) atrophic actinic keratoses showing intradnexal involvement of atypical keratinocytes (hematoxylin and eosin, ×20).

Roewert-Huber classification (9) (Table 1). The proliferative and atrophic histopathologic subtypes of AKs were detected in 33.6% and 30.4% samples, respectively. FLC was observed in 75.3% of the cases, subdivided into two categories, periadnexal (48.9%) and intraadnexal (26.4%). Periadnexal FLC was detected in 31.0% of atrophic and in 50.3% of proliferative AKs, while intraadnexal FLC was found in 48.7% and 29.2%, respectively (Figure 1, a, b). At dermoscopy, most lesions had been classified as grade I or II (38.8% and 45.8%), and only 15.4% as grade III, showing an unexpected non-response to treatment according to the dermoscopic criteria. In contrast, almost half of the AKs were classified as grade III at histology, revealing a discrepancy between the dermoscopic grading and histological findings in a majority of cases (77.4%) (Figure 2, c, d). Furthermore, atrophic and proliferative AKs accounted for 64.0% of total cases, and these are the variants associated with a higher probability of evolution toward an iSCC (10). The clinical/histological discrepancy has already been reported in the literature (9) and may represent a misleading factor for treatment choice and outcomes.






Figure 2. Discrepancy between dermoscopic (a) grading and histological findings (b) (hematoxylin and eosin, \times 20) in a sample of actinic keratoses of the face. Dermoscopy shows grade II (a), but histology shows grade III (b).

Sex (%)	Table 1. Clinical and histological features of the studied cases			
• Male • Female 73 (47.0) Age at diagnosis, mean (range) • Male • Female 72 (95-40) • Female 73 (47.0) Age at diagnosis, mean (range) • Male • Female 69 (93-41) Tumor location (%) • Face • Scalp • Scalp • Upper limb • Lower limb 6 (3.9) Grade at dermoscopy (%) • I • I • Go (38.8) • II • 71 (45.8) • II Grade at histology (%) • I • I Froilierative • Hypertrophic • Lichenoid • Acantholytic • Pigmented Intradnexal • Hypertrophic • Periadnexal • Hypertrophic • Acantholytic • Pigmented • Intradnexal • Hypertrophic • Rosonid • Acantholytic • Pigmented • Intradnexal • Hypertrophic • I (26.4) • Adnexal involvement (%) • Absent • Periadnexal • Hypertrophic • Ichenoid • T (4.5) • Pigmented • Intradnexal • Hypertrophic • I (26.4) • Poliferative • Roso.3) • Atrophic • Periadnexal • Hypertrophic • I (3.2) • Proliferative • Roso.3) • Atrophic • Periadnexal • Hypertrophic • I (3.9) • Proliferative • Pigmented • Intradnexal • Hypertrophic • I (3.9) • Proliferative • Pigmented • Intradnexal • Hypertrophic • I (3.9) • Proliferative • Roso.3) • Atrophic • Rowenoid • Intradnexal • Hypertrophic • Rosonid • I (2.4) • Hypertrophic • I (3.9) • Proliferative • Pigmented • Intradnexal • Hypertrophic • Rosonid • A (2.4) • Hypertrophic • I (3.9) • Proliferative • Pigmented • Intradnexal • Hypertrophic • Rosonid • A (2.4) • Pigmented • Intradnexal • Hypertrophic • Rosonid • A (2.4) • Pigmented • Intradnexal • Hypertrophic • Rosonid • A (2.4) • Pigmented • Intradnexal • Hypertrophic • Rosonid • A (2.4) • Pigmented • Intradnexal • Rosonid • A (2.4) • Pigmented • Intradnexal • Rosonid • A (2.4) • Pigmented • Intradnexal • Rosonid • A (2.4) • Pigmented • Intradnexal • Rosonid • A (2.4) • Pigmented • Intradnexal • Rosonid • A (2.4) • Pigmented • Intradnexal • Rosonid • A (2.4) • Pigmented • Intradnexal • Rosonid • A (2.4) • Pigmented • Rosonid • A (2.4) • Pigmented				
• Female Age at diagnosis, mean (range) • Male • Female F	Sex (%)	Mala	92 (52 0)	
Age at diagnosis, mean (range) • Male • Female 69 (93-41) Tumor location (%) • Face • Scalp • Chest • Chest • Upper limb • Lower limb Grade at dermoscopy (%) • I • II 71 (45.8) • Hypertrophic 12 (7.7) • Lichenoid 15 (9.7) • Proliferative 52 (33.6) • Atrophic • Poriadnexal • Periadnexal • Periadnexal • Periadnexal • Periadnexal • Periadnexal • Intradnexal • Hypertrophic • So (3.2) • Proliferative 78 (50.3) • Atrophic • Rowenoid • Atrophic • Periadnexal • Hypertrophic • Periadnexal • Hypertrophic • So (3.2) • Proliferative 78 (50.3) • Atrophic • Acantholytic • Pigmented 6 (3.9) • Intradnexal • Hypertrophic 15 (9.7) • Lichenoid • Acantholytic • Pigmented 6 (3.9) • Intradnexal • Hypertrophic 15 (9.7) • Lichenoid • Acantholytic • Pigmented 6 (3.9) • Intradnexal • Hypertrophic • Pigmented 6 (3.9) • Intradnexal • Hypertrophic • Pigmented 6 (3.9) • Intradnexal • Acantholytic • Pigmented 6 (3.9) • Intradnexal • Acantholytic • Pigmented 5 (3.2) • Proliferative 7 (4.5) • Atrophic • Acantholytic • Pigmented 5 (3.9) • Absent • Absent • Acantholytic • Pigmented 5 (
 Male Female 72 (95-40) Female 69 (93-41) Tumor location (%) Face 84 (54.2) Scalp 31 (20.0) Chest 20 (12.9) Upper limb 14 (9.0) Lower limb 6 (3.9) Grade at dermoscopy (%) I 60 (38.8) II 71 (45.8) II 24 (15.4) Grade at histology (%) I 57 (36.8) II 21 (13.5) III 21 (13.5) III 77 (49.7) Histologic variants (%) Hypertrophic 12 (7.7) Lichenoid 15 (9.7) Proliferative 52 (33.6) Atrophic 47 (30.4) Bowenoid 8 (5.1) Acantholytic 7 (4.5) Pigmented 14 (9.0) Adnexal involvement (%) Absent 46 (24.7) Periadnexal 68 (48.9) Intradnexal 41 (26.4) Adrophic 48 (31.0) Porliferative 78 (50.3) Atrophic 48 (31.0) Popigmented 6 (3.9) Intradnexal 4 (2.4) Pigmented 75 (48.7) Pigmented 75 (48.7) Pigmented 75 (48.7) Atrophic 15 (9.7) Lichenoid 45 (29.2) Proliferative 75 (48.7) Atrophic 15 (9.7) Lichenoid 45 (29.2) Proliferative 75 (48.7) Atrophic 75 (48.7	10(11)			
• Female 69 (93-41) Tumor location (%) • Face 84 (54.2) • Scalp 31 (20.0) • Chest 20 (12.9) • Upper limb 14 (9.0) • Lower limb 6 (3.9) Grade at dermoscopy (%) • I 60 (38.8) • II 71 (45.8) • II 24 (15.4) Grade at histology (%) • I 57 (36.8) • II 21 (13.5) • III 77 (49.7) Histologic variants (%) • Hypertrophic 12 (7.7) • Lichenoid 15 (9.7) • Proliferative 52 (33.6) • Atrophic 47 (30.4) • Bowenoid 8 (5.1) • Acantholytic 7 (4.5) • Pigmented 14 (9.0) Adnexal involvement (%) • Absent 46 (24.7) • Periadnexal 41 (26.4) Adnexal involvement according to the histologic subtype (%) • Periadnexal • Hypertrophic 5 (3.2) • Proliferative 78 (50.3) • Atrophic 48 (31.0) • Acantholytic 6 (3.9) • Pigmented 6 (3.9) • Intradnexal 4 (2.4) • Hypertrophic 15 (9.7) • Lichenoid 75 (4.5) • Acantholytic 6 (3.9) • Proliferative 78 (50.3) • Atrophic 48 (31.0) • Bowenoid 7 (4.5) • Acantholytic 6 (3.9) • Pigmented 6 (3.9) • Intradnexal 4 (2.4) • Hypertrophic 15 (9.7) • Lichenoid 45 (29.2) • Proliferative 75 (48.7) • Atrophic 0 (0.0) • Bowenoid 4 (2.4) • Atrophic 75 (48.7) • Atrophic 10 (0.0) • Bowenoid 4 (2.4) • Acantholytic 75 (36.9) • Absent 48 (31.0) • Scarce 57 (36.9) • Moderate 48 (31.0)	Age at ur	_	72 (95-40)	
Tumor location (%) Face	•			
• Face • Scalp • Scalp • Chest • Chest • Upper limb • Lower limb 6 (3.9) Grade at dermoscopy (%) • I • II				
 Chest	•		84 (54.2)	
• Upper limb • Lower limb 6 (3.9) Grade at dermoscopy (%) • I 60 (38.8) • II 71 (45.8) • II 24 (15.4) Grade at histology (%) • I 57 (36.8) • II 21 (13.5) • III 77 (49.7) Histologic variants (%) • Hypertrophic 12 (7.7) • Lichenoid 15 (9.7) • Proliferative 52 (33.6) • Atrophic 47 (30.4) • Bowenoid 8 (5.1) • Acantholytic 7 (4.5) • Pigmented 14 (9.0) Adnexal involvement (%) • Absent 46 (24.7) • Periadnexal 68 (48.9) • Intradnexal 41 (26.4) Adnexal involvement according to the histologic subtype (%) • Periadnexal • Hypertrophic 5 (3.2) • Proliferative 78 (50.3) • Atrophic 48 (31.0) • Bowenoid 7 (4.5) • Acantholytic 6 (3.9) • Intradnexal 4 (2.4) • Pigmented 6 (3.9) • Intradnexal 4 (2.4) • Hypertrophic 15 (9.7) • Lichenoid 45 (29.2) • Proliferative 75 (48.7) • Lichenoid 45 (29.2) • Proliferative 75 (48.7) • Acantholytic 10 (0.0) • Bowenoid 4 (2.4) • Acantholytic 12 (7.6) • Pigmented Solar elastosis (%) • Absent 48 (31.0) • Scarce 57 (36.9) • Moderate	•	Scalp	31 (20.0)	
■ Lower limb 6 (3.9) Grade at dermoscopy (%) ■	•		20 (12.9)	
Grade at dermoscopy (%) I	•			
■ I	•		6 (3.9)	
■ II 71 (45.8) ■ II 24 (15.4) Grade at histology (%) ■ I 57 (36.8) ■ II 21 (13.5) ■ III 77 (49.7) Histologic variants (%) ■ Hypertrophic 12 (7.7) ■ Lichenoid 15 (9.7) ■ Proliferative 52 (33.6) ■ Atrophic 47 (30.4) ■ Bowenoid 8 (5.1) ■ Acantholytic 7 (4.5) ■ Pigmented 14 (9.0) Adnexal involvement (%) ■ Absent 46 (24.7) ■ Periadnexal 68 (48.9) ■ Intradnexal 41 (26.4) Adnexal involvement according to the histologic subtype (%) ■ Periadnexal ■ Hypertrophic 5 (3.2) ■ Proliferative 78 (50.3) ■ Atrophic 48 (31.0) ■ Bowenoid 7 (4.5) ■ Acantholytic 6 (3.9) ■ Pigmented 6 (3.9) ■ Intradnexal 4 (2.4) ■ Hypertrophic 15 (9.7) ■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Acantholytic 12 (7.6) ■ Bowenoid 4 (2.4) ■ Acantholytic 12 (7.6) ■ Pigmented Solar elastosis (%) ■ Absent 48 (31.0) ■ Scarce 57 (36.9) ■ Moderate	Grade at dermoscopy (%)			
■ II	•	•		
Grade at histology (%) I 57 (36.8) II 21 (13.5) III 77 (49.7) Histologic variants (%) Hypertrophic 12 (7.7) Lichenoid 15 (9.7) Proliferative 52 (33.6) Atrophic 47 (30.4) Bowenoid 8 (5.1) Acantholytic 7 (4.5) Pigmented 14 (9.0) Adnexal involvement (%) Absent 46 (24.7) Periadnexal 68 (48.9) Intradnexal 41 (26.4) Adnexal involvement according to the histologic subtype (%) Periadnexal 5 (3.2) Proliferative 78 (50.3) Atrophic 48 (31.0) Bowenoid 7 (4.5) Acantholytic 6 (3.9) Acantholytic 6 (3.9) Pigmented 6 (3.9) Intradnexal 4 (2.4) Hypertrophic 15 (9.7) Lichenoid 45 (29.2) Proliferative 75 (48.7) Atrophic 0 (0.0) Bowenoid 4 (2.4) Atrophic 12 (7.6) Pigmented 5 (3.9) Atrophic 15 (9.7) Atrophic 15 (9.7) Lichenoid 45 (29.2) Proliferative 75 (48.7) Atrophic 0 (0.0) Bowenoid 4 (2.4) Acantholytic 12 (7.6) Pigmented 5 (36.9) Absent 48 (31.0) Scarce 57 (36.9) Moderate 42 (27.0)	•			
■ I	Crada at		24 (13.4)	
■ II	Ji aue at	riistology (%)	57 (36.8)	
■ III 77 (49.7) Histologic variants (%) ■ Hypertrophic 12 (7.7) ■ Lichenoid 15 (9.7) ■ Proliferative 52 (33.6) ■ Atrophic 47 (30.4) ■ Bowenoid 8 (5.1) ■ Acantholytic 7 (4.5) ■ Pigmented 14 (9.0) Adnexal involvement (%) ■ Absent 46 (24.7) ■ Periadnexal 68 (48.9) ■ Intradnexal 41 (26.4) Adnexal involvement according to the histologic subtype (%) ■ Periadnexal ■ Hypertrophic 5 (3.2) ■ Proliferative 78 (50.3) ■ Atrophic 48 (31.0) ■ Bowenoid 7 (4.5) ■ Acantholytic 6 (3.9) ■ Pigmented 6 (3.9) ■ Intradnexal 4 (2.4) ■ Hypertrophic 15 (9.7) ■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Atrophic 0 (0.0) ■ Bowenoid 4 (2.4) ■ Atrophic 12 (7.6) ■ Pigmented Solar elastosis (%) ■ Absent 48 (31.0) ■ Scarce 57 (36.9) ■ Moderate	•	i l		
Histologic variants (%)	•	**		
 Hypertrophic Lichenoid Proliferative Atrophic Atrophic Bowenoid Kotantholytic Pigmented Adnexal involvement (%) Absent Periadnexal Intradnexal Hypertrophic Lichenoid Hypertrophic Lichenoid Acantholytic Proliferative Atrophic Atrophic Acantholytic Pigmented Hypertrophic Solan elastosis (%) Absent Absent Absent Absent Acantholytic Acantholytic<td colspan="3"></td>				
 Lichenoid Proliferative Atrophic Bowenoid Acantholytic Pigmented Absent Periadnexal Hypertrophic Bowenoid Acantholytic Proliferative Acantholytic Periadnexal Hypertrophic Lichenoid Proliferative Acantholytic Pigmented Hypertrophic Lichenoid Folareative Acantholytic Acantholytic Pigmented Hypertrophic Solar elastosis (%) Absent Absent Absent Absent Absent Absent Moderate Moderate 15 (9.7) 12 (7.6) 	•		12 (7.7)	
 Atrophic Bowenoid Acantholytic Pigmented 14 (9.0) Adnexal involvement (%) Absent Periadnexal Intradnexal Al (26.4) Adnexal involvement according to the histologic subtype (%) Periadnexal Hypertrophic Lichenoid Proliferative Atrophic Atrophic Acantholytic Pigmented Intradnexal Hypertrophic 5 (3.2) Ecantholytic Acantholytic Acantholytic Pigmented 43.9) Intradnexal Hypertrophic Fig.7) Lichenoid 45 (29.2) Proliferative Actophic Actophic Actophic Actophic Acantholytic Pigmented Solar elastosis (%) Absent Scarce Moderate 42 (27.0) 	•			
 Bowenoid Acantholytic Pigmented 14 (9.0) Adnexal involvement (%) Absent Periadnexal Intradnexal Al (26.4) Adnexal involvement according to the histologic subtype (%) Periadnexal Hypertrophic Lichenoid Proliferative Atrophic Atrophic Acantholytic Pigmented Intradnexal Hypertrophic 5 (3.2) Proliferative A(50.3) Atrophic Hy (3.9) Intradnexal Hypertrophic Figmented 45 (29.2) Proliferative Atrophic Atrophic Acantholytic Bowenoid Acantholytic Pigmented Solar elastosis (%) Absent Scarce Moderate 42 (27.0) 	•	Proliferative	52 (33.6)	
 Acantholytic Pigmented Adnexal involvement (%) Absent Periadnexal Intradnexal Adnexal involvement according to the histologic subtype (%) Periadnexal Hypertrophic Lichenoid Proliferative Atrophic Acantholytic Pigmented Intradnexal Hypertrophic 5 (3.2) Proliferative A(50.3) Atrophic Acantholytic Figmented (3.9) Intradnexal Hypertrophic F(9.7) Lichenoid Hypertrophic F(9.7) Lichenoid Atrophic Atrophic Acantholytic Pigmented Solar elastosis (%) Absent Scarce Moderate 42 (27.0) 	•	Atrophic	47 (30.4)	
 ▶ Pigmented Adnexal involvement (%) ▶ Absent ▶ Periadnexal ▶ Intradnexal ♣ Intradnexal ♣ Intradnexal Adnexal involvement according to the histologic subtype (%) ▶ Periadnexal ♣ Hypertrophic ♣ Lichenoid ♣ Bowenoid ♣ Atrophic ♣ Bowenoid ♣ Acantholytic ♣ Acantholytic ♠ Intradnexal ♣ Hypertrophic ♣ Hypertrophic ♣ Figure 15 (9.7) ♣ Lichenoid ♣ 5 (29.2) ♣ Proliferative ♣ Atrophic ♠ Atrophic ♠ Acantholytic ♣ Bowenoid ♣ Acantholytic ♣ Pigmented Solar elastosis (%) ♠ Absent ♠ Scarce ♠ Moderate 	•	Bowenoid		
Adnexal involvement (%)	•	-		
 Absent Periadnexal Intradnexal Adnexal involvement according to the histologic subtype (%) Periadnexal Hypertrophic Lichenoid Proliferative Acantholytic Pigmented Hypertrophic 3.2) Proliferative Acantholytic Acantholytic Pigmented (3.9) Intradnexal Hypertrophic Fyo7) Lichenoid 45 (29.2) Proliferative Atrophic Acantholytic Pigmented 45 (29.2) Proliferative Acantholytic Pigmented 	•	_	14 (9.0)	
 Periadnexal Intradnexal Adnexal involvement according to the histologic subtype (%) Periadnexal Hypertrophic Lichenoid Proliferative Acantholytic Pigmented Hypertrophic 3.2) Proliferative Acantholytic Acantholytic Hypertrophic Fignal 45 (29.2) Proliferative Atrophic Acantholytic Pigmented Solar elastosis (%) Absent Scarce Moderate 	Adnexal i			
■ Intradnexal 41 (26.4) Adnexal involvement according to the histologic subtype (%) ■ Periadnexal ■ Hypertrophic 5 (3.2) ■ Lichenoid 5 (3.2) ■ Proliferative 78 (50.3) ■ Atrophic 48 (31.0) ■ Bowenoid 7 (4.5) ■ Acantholytic 6 (3.9) ■ Pigmented 6 (3.9) ■ Intradnexal 4 (2.4) ■ Hypertrophic 15 (9.7) ■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Atrophic 0 (0.0) ■ Bowenoid 4 (2.4) ■ Acantholytic 12 (7.6) ■ Pigmented Solar elastosis (%) ■ Absent 48 (31.0) ■ Scarce 57 (36.9) ■ Moderate 42 (27.0)	•			
Adnexal involvement according to the histologic subtype (%) Periadnexal Hypertrophic Lichenoid Froliferative Solar elastosis (%) Adnexal Hypertrophic Signary	•			
histologic subtype (%) Periadnexal Hypertrophic	Adpovali		41 (20.4)	
 Periadnexal Hypertrophic Lichenoid 78 (50.3) Atrophic Bowenoid Acantholytic Pigmented Hypertrophic Hypertrophic Hypertrophic Lichenoid Hypertrophic Lichenoid Proliferative Atrophic Atrophic Proliferative Acantholytic Acantholytic Bowenoid Acantholytic Pigmented Solar elastosis (%) Absent Scarce Moderate 	=			
 Hypertrophic Lichenoid Proliferative Atrophic Bowenoid Acantholytic Hypertrophic Pigmented Hypertrophic Hypertrophic Lichenoid Proliferative Proliferative Atrophic Atrophic Atrophic Atrophic Atrophic Acantholytic Pigmented 	•	* -		
■ Lichenoid 5 (3.2) ■ Proliferative 78 (50.3) ■ Atrophic 48 (31.0) ■ Bowenoid 7 (4.5) ■ Acantholytic 6 (3.9) ■ Pigmented 6 (3.9) ■ Intradnexal 4 (2.4) ■ Hypertrophic 15 (9.7) ■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Atrophic 0 (0.0) ■ Bowenoid 4 (2.4) ■ Acantholytic 12 (7.6) ■ Pigmented Solar elastosis (%) ■ Absent 48 (31.0) ■ Scarce 57 (36.9) ■ Moderate 42 (27.0)			5 (3.2)	
■ Proliferative 78 (50.3) ■ Atrophic 48 (31.0) ■ Bowenoid 7 (4.5) ■ Acantholytic 6 (3.9) ■ Pigmented 6 (3.9) ■ Intradnexal 4 (2.4) ■ Hypertrophic 15 (9.7) ■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Atrophic 0 (0.0) ■ Bowenoid 4 (2.4) ■ Acantholytic 12 (7.6) ■ Pigmented Solar elastosis (%) ■ Absent 48 (31.0) ■ Scarce 57 (36.9) ■ Moderate 42 (27.0)		• • •		
 Atrophic Bowenoid 7 (4.5) Acantholytic Pigmented (3.9) Intradnexal Hypertrophic Lichenoid Proliferative Atrophic Acantholytic Pigmented Solar elastosis (%) Absent Scarce Moderate 48 (31.0) 7 (4.5) 7 (4.5) 4 (2.4) 12 (7.6) 57 (36.9) 42 (27.0) 				
 Acantholytic Pigmented (3.9) Intradnexal Hypertrophic Lichenoid Proliferative Atrophic Bowenoid Acantholytic Pigmented Solar elastosis (%) Absent Scarce Moderate (6 (3.9) (2.4) (15 (9.7) (48.7) (10.0) (10.0)		 Atrophic 		
■ Pigmented 6 (3.9) ■ Intradnexal 4 (2.4) ■ Hypertrophic 15 (9.7) ■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Atrophic 0 (0.0) ■ Bowenoid 4 (2.4) ■ Acantholytic 12 (7.6) ■ Pigmented Solar elastosis (%) ■ Absent 48 (31.0) ■ Scarce 57 (36.9) ■ Moderate 42 (27.0)		Bowenoid	7 (4.5)	
 Intradnexal Hypertrophic Lichenoid Proliferative Atrophic Bowenoid Acantholytic Pigmented Solar elastosis (%) Absent Scarce Moderate 4 (2.4) 12 (7.6) 57 (36.9) 48 (31.0) 57 (36.9) 42 (27.0) 		•		
 Hypertrophic Lichenoid Proliferative Atrophic Bowenoid Acantholytic Pigmented Absent Scarce Moderate 15 (9.7) 45 (29.2) 75 (48.7) 0 (0.0) 4 (2.4) 12 (7.6) 48 (31.0) 57 (36.9) 42 (27.0) 				
■ Lichenoid 45 (29.2) ■ Proliferative 75 (48.7) ■ Atrophic 0 (0.0) ■ Bowenoid 4 (2.4) ■ Acantholytic 12 (7.6) ■ Pigmented Solar elastosis (%) ■ Absent 48 (31.0) ■ Scarce 57 (36.9) ■ Moderate 42 (27.0)	•			
Proliferative 75 (48.7) Atrophic 0 (0.0) Bowenoid 4 (2.4) Acantholytic 12 (7.6) Pigmented Solar elastosis (%) Absent 48 (31.0) Scarce 57 (36.9) Moderate 42 (27.0)				
 Atrophic 0 (0.0) Bowenoid 4 (2.4) Acantholytic 12 (7.6) Pigmented Solar elastosis (%) Absent 48 (31.0) Scarce 57 (36.9) Moderate 42 (27.0) 				
Bowenoid 4 (2.4) Acantholytic 12 (7.6) Pigmented Solar elastosis (%) Absent 48 (31.0) Scarce 57 (36.9) Moderate 42 (27.0)				
■ Acantholytic ■ Pigmented Solar elastosis (%) ■ Absent ■ Scarce ■ Moderate 12 (7.6) 48 (31.0) 57 (36.9) 42 (27.0)		-		
Pigmented Solar elastosis (%) Absent Scarce Moderate Pigmented 48 (31.0) 57 (36.9) 42 (27.0)				
Solar elastosis (%)		=	- \ /	
 Absent 48 (31.0) Scarce 57 (36.9) Moderate 42 (27.0) 	Solar elastosis (%)			
ScarceModerate57 (36.9)42 (27.0)	•		48 (31.0)	
	•	Scarce		
• Severe 8 (5.1)	•	Moderate	42 (27.0)	
	•	Severe	8 (5.1)	

Table 1. Clinical and histological features of the

We believe that a comparative analysis with dermoscopy and histology should be performed in non-responding AKs, in order to choose the best therapeutic option. In fact, some superficial treatments (such as cryotherapy) may not provide a good response in deep hair follicles (4). We also suggest encouraging greater focus on FLC and its description in pathology reports.

This is a preliminary observational study, but it reinforces the need to further larger clinical studies investigating the role of specific histopathologic parameters in AKs, including FLC, that may correlate with treatment outcomes.

ACKNOWLEDGEMENTS:

The patients in this manuscript have given written informed consent to publication of their case details.

References:

- Jansen MHE, Kessels J, Nelemans PJ, Kouloubis N, Arits, AH, Pelt HP, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380:935-46.
- Zalaudek I, Piana S, Moscarella E, Longo C, Zendri E, Castagnetti F, et al. Morphologic grading and treatment of facial actinic keratosis. Clin Dermatol. 2014;32:80-7.
- Fernández-Figueras MT, Carrato C, Saenz X, Puig L, Musulen E, Ferrandiz C, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29:991-7.
- Fernández-Figueras MT, Saenz-Sarda X, Vargas P, Thompson CT, Carrato C, Puig L, et al. The depth of follicular extension in actinic keratosis correlates with the depth of invasion in squamous cell carcinoma: implication for clinical treatment. J Eur Acad Dermatol Venereol. 2018;32:1657-61.
- 5. Pandey S, Mercer SE, Dallas K, Emanuel PO, Goldenberg G. Evaluation of the prognostic significance of follicular extension in actinic keratoses. J Clin Aesthetic Dermatol. 2012;5:25-8.
- Dika E Veronesi G, Miscialli C, Corti B, Dika I, Riefolo M, , et al. Malignant melanoma cells and hair follicles. Am J Clin Pathol. 2019;152:109-14.

- 7. Dika E, Patrizi A, Veronesi G, Manuelpillai N, Lambertini M. Malignant cutaneous tumors of the scalp: always remember to examine the head. J Eur Acad Dermatol Venereol. 2020;34:2208-15.
- 8. Lyle S. Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc. 1999;4:296-301.
- 9. Lee DW. Correlations between histopathologic and dermoscopic findings in Korean actinic keratosis. Microsc Res Tech. 2019;82:12-7.
- 10. Goldberg LH, Chang JR, Baer SC, Schmidt JD. Proliferative Actinic Keratosis: Three Representative Cases. Dermatol Surg.2000;26:65-9.

Emi Dika^{1,2*}, Martina Lambertini^{1,2*}, Giulia Veronesi^{1,2}, Cosimo Misciali¹, Massimo Milani¹, Aleksandra Bergant-Suhodolcan^{3,4}, Bor Hrvatin Stancic^{3,4}, Carlotta Baraldi^{1,2*}

*Equal contribution

¹Division of Dermatology, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italia
²Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Italy
³Dermatovenerology Department, University Medical Centre Ljubljana, Slovenia
⁴Faculty of Medicine, University of Ljubljana, Slovenia

Corresponding author:

Martina Lambertini, MD
Department of Experimental, Diagnostic and
Specialty Medicine, University of Bologna
Via Massarenti, 1 – 40138 Bologna,
Italy
mlambertini@hotmail.it

Received: November 22, 2022 Accepted: June 1, 2023